Literature DB >> 15281229

Effects of pirfenidone on the generation of reactive oxygen species in vitro.

S N Giri1, S Leonard, X Shi, S B Margolin, V Vallyathan.   

Abstract

Pirfenidone is a newly developed antifibrotic drug that has been reported to retard the progression of pulmonary fibrosis induced by bleomycin and cyclophosphamide in animal models of lung fibrosis. The present in vitro studies using noncellular and cellular systems evaluated the antioxidant and cytotoxic properties of this drug. The Fenton reaction [Fe(II) + H2O2 --> Fe(III) + *OH + OH-] and the xanthine/xanthine oxidase system were used as sources of hydroxyl (*OH) and superoxide anion (O2*-) radicals, respectively. Electron spin resonance spin trapping was used for free radical detection and measurement. The reaction rate of pirfenidone with *OH was found to be 1.63 x 10(10) M(-1) s(-1), which is comparable to several well-established antioxidants, such as ascorbate, glutathione, cysteine, azide, and lipoic acid. Compared to *OH radicals, the O2*- scavenging was less efficient 42.36 M(-1) s(-1) with pirfenidone. Pirfenidone was also effective in inhibiting zymosan-stimulated chemiluminescence. In a noncellular model of lipid peroxidation, pirfenidone inhibited crystalline silica-induced lipid peroxidation. The inhibition of crystalline silica-induced cytotoxic reactions and lipid peroxidation combined with the efficient antioxidant properties of pirfenidone indicate that this agent may express its antifibrotic effects partly through its ability to scavenge reactive oxygen species.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 15281229

Source DB:  PubMed          Journal:  J Environ Pathol Toxicol Oncol        ISSN: 0731-8898            Impact factor:   3.567


  23 in total

Review 1.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

2.  Antifibrotic effects of pirfenidone on Tenon's fibroblasts in glaucomatous eyes: comparison with mitomycin C and 5-fluorouracil.

Authors:  Jung Hwa Na; Kyung Rim Sung; Jin A Shin; Jung Il Moon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-06-07       Impact factor: 3.117

3.  Redox Imbalance in Idiopathic Pulmonary Fibrosis: A Role for Oxidant Cross-Talk Between NADPH Oxidase Enzymes and Mitochondria.

Authors:  Carmen Veith; Agnes W Boots; Musa Idris; Frederik-Jan van Schooten; Albert van der Vliet
Journal:  Antioxid Redox Signal       Date:  2019-04-05       Impact factor: 8.401

Review 4.  Pirfenidone: in idiopathic pulmonary fibrosis.

Authors:  Natalie J Carter
Journal:  Drugs       Date:  2011-09-10       Impact factor: 9.546

5.  Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation.

Authors:  S N Iyer; D M Hyde; S N Giri
Journal:  Inflammation       Date:  2000-10       Impact factor: 4.092

Review 6.  Pirfenidone: a review of its use in idiopathic pulmonary fibrosis.

Authors:  Esther S Kim; Gillian M Keating
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

7.  Pirfenidone is renoprotective in diabetic kidney disease.

Authors:  Satish P RamachandraRao; Yanqing Zhu; Timothy Ravasi; Tracy A McGowan; Irene Toh; Stephen R Dunn; Shinichi Okada; Michael A Shaw; Kumar Sharma
Journal:  J Am Soc Nephrol       Date:  2009-07-02       Impact factor: 10.121

Review 8.  Antifibrosis: to reverse the irreversible.

Authors:  Ziv Paz; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

9.  Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials.

Authors:  Chunguo Jiang; Hui Huang; Jia Liu; Yanxun Wang; Zhiwei Lu; Zuojun Xu
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

Review 10.  Novel therapeutic approaches for pulmonary fibrosis.

Authors:  Arnab Datta; Chris J Scotton; Rachel C Chambers
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.